A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Capecitabine (Primary) ; Eribulin (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CENTER
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 03 Sep 2021 New trial record